Penza State University
🇷🇺Russia
- Country
- 🇷🇺Russia
- Ownership
- Private
- Established
- 1943-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- https://pnzgu.ru
Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 4:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (66.7%)Not Applicable
1 (33.3%)Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19
Not Applicable
Active, not recruiting
- Conditions
- STEMICovid19NSTEMI
- Interventions
- Drug: Atorvastatin-Ezetimibe
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Penza State University
- Target Recruit Count
- 45
- Registration Number
- NCT04900155
- Locations
- 🇷🇺
Valentin Oleynikov, Penza, Russian Federation
Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
Phase 4
Recruiting
- Conditions
- Myocardial StrainArterial StiffnessMyocardial Infarction, AcuteQuality of Life
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Penza State University
- Target Recruit Count
- 300
- Registration Number
- NCT04347434
- Locations
- 🇷🇺
Valentin Oleynikov, Penza, Russian Federation
Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Penza State University
- Target Recruit Count
- 200
- Registration Number
- NCT02590653
- Locations
- 🇷🇺
Valentin Oleynikov, Penza, Russian Federation
News
No news found